Breaking News Instant updates and real-time market news.

STLD

Steel Dynamics

$23.89

0.16 (0.67%)

, NRG

NRG Energy

$11.24

0.27 (2.46%)

09:40
10/18/16
10/18
09:40
10/18/16
09:40

Unusually active option classes on open October 18th

Unusual total active option classes on open include: Steel Dynamics (STLD), NRG Energy (NRG), E Trade (ETFC), Avis Budget (CAR), ProShares UltraShort S&P 500 (SDS), UnitedHealthcare (UNH), Netflix (NFLX), IBM (IBM), Golar LNG (GLNG), and Teva (TEVA).

STLD

Steel Dynamics

$23.89

0.16 (0.67%)

NRG

NRG Energy

$11.24

0.27 (2.46%)

ETFC

E-Trade

$28.13

-0.38 (-1.33%)

CAR

Avis Budget

$31.53

0.28 (0.90%)

SDS

UltraShort S&P500 ProShares

$16.81

-0.19 (-1.12%)

UNH

UnitedHealth

$141.89

7.76 (5.79%)

NFLX

Netflix

$99.80

-1.67 (-1.65%)

IBM

IBM

$148.83

-5.9425 (-3.84%)

GLNG

Golar LNG

$22.85

0.4 (1.78%)

TEVA

Teva

$42.09

0.3 (0.72%)

  • 18

    Oct

  • 20

    Oct

  • 23

    Oct

  • 04

    Nov

  • 06

    Nov

  • 14

    Nov

  • 15

    Nov

  • 29

    Nov

STLD Steel Dynamics
$23.89

0.16 (0.67%)

09/20/16
COWN
09/20/16
NO CHANGE
Target $33
COWN
Outperform
Steel Dynamics weakness would be buying opportunity, says Cowen
Cowen analyst Anthony Rizzuto said Steel Dynamics remains his top pick and should be bought on pullbacks. The analyst expects Q3 profitability to increase due to improved metal spreads. Rizzuto reiterated his Outperform rating and $33 price target on Steel Dynamics shares.
09/15/16
BOFA
09/15/16
NO CHANGE
BOFA
BofA/Merrill cautious on US steel prices correcting into 2H 2016
BofA/Merrill analyst Timma Tanners is cautious on U.S. steel prices correcting into 2H 2016 and expects foreign tons to target the U.S. to shrink the U.S. premium. The analyst lowered Q4 HRC spot price to $520/st from $570/st and trimmed 2H 2016 volume assumptions due to inventory destocking and shorter lead times. As a result, Tanners lowered price target on U.S. Steel (X) to $16 from $21 , Reliance Steel (RS) to $78 from $84, Nucor (NUE) to $50 from $55, Steel Dynamics (STLD) to $27 from $28, and Commercial Metals (CMC) to $15 from $16.
08/22/16
08/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AK Steel (AKS) initiated with a Neutral at Citi and a Buy at Rosenblatt. 2. U.S. Steel (X) and Steel Dynamics (STLD) were initiated with a Buy at Citi while the firm initiated Nucor (NUE) and Commercial Metals (CMC) with a Neutral. 3. Pinnacle Entertainment (PNK) initiated with a Buy at BofA/Merrill. 4. Ferrellgas Partners LP (FGP) initiated with a Neutral at Piper Jaffray. 5. Kadmon (KDMN) initiated with an Outperform at JMP Securities, with a Neutral at Citi, and with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/16
SBSH
08/22/16
INITIATION
Target $33
SBSH
Buy
Steel Dynamics initiated with a Buy at Citi
Citi analyst Alexander Hacking initiated Steel Dynamics with a Buy and $33 price target saying it is fundamentally undervalued relative to its sustainable ROIC.
NRG NRG Energy
$11.24

0.27 (2.46%)

06/09/16
UBSW
06/09/16
DOWNGRADE
Target $16
UBSW
Sell
NRG Energy downgraded to Sell from Buy at UBS
UBS analyst Julien Dumoulin-Smith double downgraded NRG Energy to Sell from Buy saying the stock's risk/reward "skews negatively" following the near doubling off the January lows. The market is overlooking the $285M decrease in PJM capacity revenue, Dumoulin-Smith tells investors in a research note. He has a $16 price target for the shares.
05/25/16
MSCO
05/25/16
NO CHANGE
MSCO
Morgan Stanley says to buy Dynegy, NRG Energy on any weakness
Morgan Stanley analyst led by Stephen Byrd said results for PJM's 2019/20 Base Residual Auction came in below expectations driven by high levels of new builds. The analyst said the outcome does not materially impact his long-term auction price or the cash flow forecasts for Dynegy DYN) and NRG Energy (NRG), and would be buyers on any weakness.
01/29/16
01/29/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: American Equity (AEL) initiated with an Outperform at RBC Capital... Calpine (CPN) initiated with a Buy at Guggenheim... Diamondback Energy (FANG) initiated with an Outperform at BMO Capital... Dynegy (DYN) initiated with a Neutral at Guggenheim... ICF International (ICFI) initiated with a Market Perform at Barrington... Juno Therapeutics (JUNO) initiated with a Buy at SunTrust... Kite Pharma (KITE) initiated with a Buy at SunTrust... Match Group (MTCH) initiated with a Neutral at Susquehanna... Medifast (MED) initiated with a Hold at Wunderlich... NRG Energy (NRG) initiated with a Buy at Guggenheim... NRG Yield (NYLD) initiated with a Neutral at Guggenheim... Nutrisystem (NTRI) initiated with a Buy at Wunderlich... Parsley Energy (PE) initiated with an Outperform at BMO Capital... Precision Drilling (PDS) initiated with a Hold at Canaccord... RSP Permian (RSPP) initiated with an Outperform at BMO Capital... Taylor Morrison (TMHC) initiated with a Neutral at Citi... Tortoise North American Energy (TYN) initiated with a Neutral at Guggenheim... WisdomTree (WETF) initiated with a Neutral at Northcoast.
07/26/16
DBAB
07/26/16
UPGRADE
Target $20
DBAB
Buy
Calpine upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Abe Azar upgraded Calpine (CPN) to Buy citing valuation following the year-to-date underperformance relative to peers Dynegy (DYN) and NRG Energy (NRG). The analyst views the current valuation as "reasonable" and calls Calpine lower risk. He raised his price target for the shares to $20 from $18.
ETFC E-Trade
$28.13

-0.38 (-1.33%)

09/30/16
WELS
09/30/16
NO CHANGE
WELS
Multiple companies could pursue Scottrade, says Wells Fargo
After Bloomberg reported that Scottrade is working with an adviser to explore selling itself, and the article mentioned Ameritrade (AMTD) as a potential suitor, Wells Fargo says that Charles Schwab (SCHW) and E-Trade (ETFC) could "also have interest" in Scottrade. The firm says that the deal could be accretive by double digit percentage levels for all of the potential suitors named. However, ti says that Ameritrade "may be the most logical buyer," since E-Trade just closed on an acquisition and Schwab has sought to place less emphasis trading. The firm keeps an Outperform rating on E-Trade and Market Perform ratings on Schwab and TD Ameritrade.
09/30/16
SBSH
09/30/16
NO CHANGE
Target $31.5
SBSH
Neutral
Citi 'inclined to fade' September rally in TD Ameritrade
Citi analyst William Katz attributes the 5% September rally in shares of TD Ameritrade (AMTD) to speculation around a possible acquisition of E-Trade (ETFC). The rally in the shares likely discounts the earnings accretion from such a merger, Katz tells investors in a research note. He believes TD Ameritrade shares at current levels leave "no room for a bad outcome," which he defines as the company deciding not to pursue the deal or E-Trade acquiring Scottrade. As such, Katz says he's "inclined to fade the rally" in TD Ameritrade. The analyst has a Neutral rating on the shares with a $31.50 price target. TD Ameritrade is up 2% in early trading to $35.08.
10/13/16
BOFA
10/13/16
DOWNGRADE
Target $33
BOFA
Neutral
E-Trade downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Michael Carrier downgraded E-Trade to Neutral and raised its price target to $33 from $31.
10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CAR Avis Budget
$31.53

0.28 (0.90%)

09/27/16
MKMP
09/27/16
NO CHANGE
MKMP
Avis Budget weakness a buying opportunity, says MKM Partners
MKM Partners recommends buying Avis Budget Group on weakness following the company's presentation at the Deutsche Bank conference and comments regarding demand weakness in Europe. The firm's analyst said pricing in North America far outweighs the impact elsewhere and maintains its Buy rating.
08/25/16
MACQ
08/25/16
INITIATION
Target $44
MACQ
Outperform
Avis Budget initiated with an Outperform at Macquarie
Macquarie analyst Hamzah Mazari initiated Avis Budget with an Outperform and $44 price target.
08/15/16
NRCS
08/15/16
NO CHANGE
Target $45
NRCS
Buy
Avis Budget's price target raised to $45 from $37 at Northcoast
Northcoast analyst John Healy raised Avis Budget's price target to $45 due to steadying industry fundamentals, improving industry pricing dynamics, and management's implementation of a robust cash flow and capital allocation strategy.. Healy's checks indicate industry pricing through the midpoint of August has remained in growth mode for 3Q16. The analyst has a Buy rating on Avis shares.
08/04/16
MKMP
08/04/16
NO CHANGE
MKMP
Avis Budget pricing was better than expected, says MKM Partners
MKM Partners analyst Christopher Agnew says that Avis' pricing comps turned positive sooner than expected, and he believes that this trend continued into Q3. The analyst thinks that the bears on the stock overstate the company's risks, and he keeps a $47 price target and Buy rating on the shares.
SDS UltraShort S&P500 ProShares
$16.81

-0.19 (-1.12%)

UNH UnitedHealth
$141.89

7.76 (5.79%)

09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
09/22/16
PIPR
09/22/16
NO CHANGE
Target $155
PIPR
Overweight
UnitedHealth won VA contract worth $1B per year, says Piper Jaffray
Piper Jaffray analyst Sean Wieland says UnitedHealth unit Optum has won a contract with the U.S. Department of Veterans Affairs to provide medical disability examinations. The analyst estimates the contract, awarded to Optum wholly owned subsidiaries Logistics Health and Medical Support Los Angeles, represents $1B per year. Wieland estimates the award will be neutral to earnings in year one and become accretive in 2018. He reiterates an Overweight rating on UnitedHealth shares with a $155 price target.
09/22/16
EVER
09/22/16
INITIATION
Target $155
EVER
Buy
UnitedHealth initiated with a Buy at Evercore ISI
Evercore ISI initiated UnitedHealth with a Buy and a $155 price target.
NFLX Netflix
$99.80

-1.67 (-1.65%)

10/18/16
NEED
10/18/16
NO CHANGE
NEED
Hold
Needham sees Netflix programming pivot as 'key story' of the quarter
Needham analyst Laura Martin notes that Netflix beat revenue, subscriber guidance and estimates in Q3, and sees its programming pivot as the key story of the quarter. Although the pivot toward more owned programming hurts margins and free cash flow in the near term, the analyst likes the fact that Netflix is now building a content library. Martin reiterates a Hold rating on the shares.
10/18/16
RBCM
10/18/16
NO CHANGE
RBCM
Netflix price target raised to $150 from $130 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Netflix after all of the company's guidance metrics beat expectations. The analyst thinks that the company's fundamentals are continuing to improve, and he keeps an Outperform rating on the shares.
10/18/16
ADAM
10/18/16
NO CHANGE
Target $140
ADAM
Buy
Netflix price target raised to $140 from $115 at Canaccord
Canaccord analyst Michael Graham raised his price target on Netflix to $140 from $115 following strong Q3 results. The analyst noted the subscriber growth was ahead of guidance and ahead of his own expectations. Graham also pointed to the company's plans to ramp original content more quickly and said it is still early on penetrating international markets. Graham reiterated his Buy rating on Netflix shares.
10/18/16
COWN
10/18/16
NO CHANGE
Target $150
COWN
Outperform
Netflix price target raised to $150 from $110 at Cowen
Cowen analyst John Blackledge raised his price target on Netflix to $150 from $110. The analyst cited the better than expected subscriber additions and better than expected guidance. Blackledge reiterated his Outperform rating on Netflix shares.
IBM IBM
$148.83

-5.9425 (-3.84%)

09/26/16
SOCG
09/26/16
UPGRADE
SOCG
Hold
IBM upgraded to Hold from Sell at Societe Generale
09/06/16
EVER
09/06/16
UPGRADE
Target $45
EVER
Buy
Intel upgraded to Buy from Hold at Evercore ISI
Evercore ISI analyst C.J. Muse upgraded Intel (INTC) to Buy and raised his price target for the shares to $45 from $38. The chipmaker closed Friday up 6c to $36.08. Fears of a slowdown in its Server business and sustained weakness in PCs have led Intel shares to underperform peers thus far in 2016, Muse tells investors in a research note. The analyst expects the underperformance to change as the company's Data Center Group segment accelerates to 10%+plus growth in the second half of 2016. Further, Muse thinks Intel's "competitive moat remains" despite potential competition from ARM Holdings (ARMH) and IBM's (IBM) Power9 architecture. He sees 25% upside in Intel shares from current levels.
10/18/16
FBCO
10/18/16
NO CHANGE
Target $110
FBCO
Underperform
IBM operational earnings disappoint, says Credit Suisse
Credit Suisse analyst Kulbinder Garcha said IBM reported Q3 earnings came in above expectations but operational earnings were disappointing. The analyst continues to believe 2017 earnings estimates are optimistic and reiterates his Underperform rating and $110 price target on shares.
09/23/16
OPCO
09/23/16
NO CHANGE
OPCO
Outperform
Speculation suggests Imperva takeover in 'near sight,' says Oppenheimer
Oppenheimer analyst Shaul Eyal is not surprised to see the list of potential Imperva (IMPV) buyer candidates mentioned in an article from Bloomberg, which includes Cisco (CSCO), IBM (IBM), Fortinet (FTNT), Akamai (AKAM), and privately held Forcepoint. The analyst envisions Imperva's product line aligning particularly well with Cisco's and IBM's given the recent drive by both to expand their security offerings. Eyal sees a potential price target ranging between $55-$60 if the speculation has any merit and sufficient interest from multiple bidders. Oppenheimer has an Outperform rating on Imperva's shares.
GLNG Golar LNG
$22.85

0.4 (1.78%)

09/07/16
MSCO
09/07/16
NO CHANGE
Target $30
MSCO
Overweight
Morgan Stanley has increased confidence in Golar LNG growth potential
Morgan Stanley analyst Fotis Giannakoulis has increased confidence in Golar LNG's growth potential following the creation of two new joint ventures of Golar Power with Stonepeak and OneFLNG with Schlumberger and the positive commentary on Ophir's Fortuna FLNG. The analyst reiterates his Overweight rating and increased its price target to $30 from $29 on Golar LNG shares.
08/01/16
08/01/16
UPGRADE
Target $21

Buy
Golar LNG upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Ken Hoexter upgraded Golar LNG to Buy and raised its price target to $21 from $19. The analyst believes negative news of low LNG rates, delayed new terminals, and potential financing gap are reflected in shares.
10/03/16
ABNA
10/03/16
UPGRADE
ABNA
Hold
Golar LNG upgraded to Hold from Sell at ABN Amro
08/01/16
08/01/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Golar LNG (GLNG) upgraded to Buy from Neutral at BofA/Merrill with analyst Ken Hoexter saying he believes negative news of low LNG rates, delayed new terminals, and potential financing gap are reflected in shares. 2. Coach (COH) upgraded to Positive from Mixed at OTR Global following checks that indicate steady progress by store managers, more appealing offerings, new open-to-the-public Mother's Day sale at full-price Coach stores and tight wholesale distribution. 3. Harley-Davidson (HOG) upgraded to Outperform from Market Perform at BMO Capital with analyst Gerrick Johnson saying the stock provides a good contrarian trading opportunity, given the highly negative sentiment towards it. Over the longer term, the analyst thinks that the company's accelerated development of new products will beat fruit. 4. Dollar Tree upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the Family Dollar acquisition will provide "more upside opportunities." 5. Houghton Mifflin (HMHC) upgraded to Buy from Neutral at Goldman with analyst Andre Benjamin saying the shares can rally on both positive estimate revisions and multiple expansion after underperforming year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$42.09

0.3 (0.72%)

10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.

TODAY'S FREE FLY STORIES

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

17:04
12/02/16
12/02
17:04
12/02/16
17:04
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIR

Osiris

$5.68

0.06 (1.07%)

17:02
12/02/16
12/02
17:02
12/02/16
17:02
Hot Stocks
Osiris: Nasdaq grants company's request for additional time »

Osiris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOR

STORE Capital

$24.45

0.52 (2.17%)

17:00
12/02/16
12/02
17:00
12/02/16
17:00
Hot Stocks
STORE Capital director Donovan acquires 4,350 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARB

Carbonite

$17.95

0.25 (1.41%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
Breaking Hot Stocks news story on Carbonite »

Crosslink lowers stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIB

CGI Group

$47.11

0.16 (0.34%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
CGI Group announces specific share repurchase program »

CGI Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.